Roizman B
Marjorie B. Kovler Viral Oncology Laboratories, University of Chicago, IL 60637, USA.
Proc Natl Acad Sci U S A. 1996 Oct 15;93(21):11307-12. doi: 10.1073/pnas.93.21.11307.
Herpes simplex virus vectors are being developed for delivery and expression of human genes to the central nervous system, selective destruction of cancer cells, and as carriers for genes encoding antigens that induce protective immunity against infectious agents. Vectors constructed to meet these objectives must differ from wild-type virus with respect to host range, reactivation from latency, and expression of viral genes. The vectors currently being developed are (i) helper free amplicons, (ii) replication defective viruses, and (iii) genetically engineered replication competent viruses with restricted host range. Whereas the former two types of vectors require stable, continuous cell lines expressing viral genes for their replication, the replication competent viruses will replicate on approved primary human cell strains.
单纯疱疹病毒载体正被开发用于将人类基因递送至中枢神经系统、选择性破坏癌细胞，以及作为编码可诱导针对感染因子的保护性免疫的抗原的基因载体。为实现这些目标构建的载体在宿主范围、潜伏激活以及病毒基因表达方面必须与野生型病毒有所不同。目前正在开发的载体有：（i）无辅助病毒扩增子，（ii）复制缺陷型病毒，以及（iii）宿主范围受限的基因工程复制型病毒。前两类载体的复制需要表达病毒基因的稳定、连续细胞系，而复制型病毒可在经批准的原代人细胞株上复制。
